Refine your search
1,202 results found
Pearce IP | Australia, European Union, India, etc. | 27 Nov 2023
BioBlast w/e 24 Nov 23
Celltrion revealed in a corporate filing with the Repository of Korea’s Corporate Filings (DART) that it has applied for marketing authorisation in…
Pearce IP | European Union | 24 Nov 2023
Celltrion Applies For EU Approval of CT-P43, Biosimilar to Regeneron’s Eylea® (aflibercept)
Celltrion revealed in a corporate filing with the Repository of Korea’s Corporate Filings (DART) that it has applied for marketing authorisation in…
Pearce IP | India | 24 Nov 2023
Enzene Launches Ranibizumab Biosimilar in India
Express Pharma reported that Enzene Biosciences has launched its biosimilar ranibizumab in India (biosimilar to Genentech’s Lucentis®) for the…
Pearce IP | South Korea | 15 Nov 2023
Samsung Bioepis SB27, Keytruda® (pembrolizumab) Biosimilar Enters the Clinic
The Korea Herald reported that Samsung Bioepis has received approval from the Ministry of Food and Drug Safety for a phase I clinical trial of SB27…
Pearce IP | Canada | 14 Nov 2023
First Biosimilar Approval Alert: Health Canada Approves Alvotech’s AVT04 commercialised by JAMP as Jamteki™, the First Stelara® (ustekinumab) Biosimilar in Canada
Alvotech and JAMP Pharma announced that Health Canada has granted marketing authorization for Jamteki™ (AVT04), the first approved biosimilar to…
Pearce IP | Australia | 13 Nov 2023
Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Lucentis® (Ranibizumab) Biosimilar
Lupin Limited announced that it has executed an agreement with the pharmaceutical manufacturer Amman Pharmaceuticals Industries for exclusive…
Pearce IP | India | 10 Nov 2023
Biocon Revenue from Biosimilars up 97%
Biocon announced its consolidated financial results, including a 97% increase in revenue year on year for its Biologics business unit. Biocon…
Pearce IP | Germany | 9 Nov 2023
Sandoz Opens Biosimilar Development Centre in Germany
Sandoz announced the inauguration of its new Biosimilar Development Center in Holzkirchen, Germany. Sandoz invested €25 million in the Holzkirchen…
Pearce IP | European Union | 1 Nov 2023
Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar
Fresenius Kabi announced it has launched Tyenne®, the first EC-approved biosimilar to Roche’s Actemra®/RoActemra® in the EU. Tyenne® was approved by…
Pearce IP | USA | 31 Oct 2023
Approval Alert: FDA Approves First Ustekinumab Biosimilar (Amgen)
On 31 October 2023, the FDA approved Amgen’s Wezlana® (ustekinumab-auub), as the first FDA-approved biosimilar to Janssen’s Stelara®. Wezlana is…
